F-031
Fluconazole solution
2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C13H12F2N6O
Numéro CAS:
Poids moléculaire :
306.27
Numéro CE :
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
certified reference material
Niveau de qualité
Forme
liquid
Caractéristiques
(Snap-N-Spike®)
Conditionnement
ampule of 1 mL
Fabricant/nom de marque
Cerilliant®
Concentration
2.0 mg/mL in methanol
Technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Application(s)
clinical testing
Format
single component solution
Température de stockage
−20°C
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
Clé InChI
RFHAOTPXVQNOHP-UHFFFAOYSA-N
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Description générale
Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.
Application
- Gas chromatography-mass spectrometry determination of conjugated linoleic acids and cholesterol oxides and their stability in a model system.: This study employs the Equity-5 Capillary GC Column to determine conjugated linoleic acids and cholesterol oxides, demonstrating the column′s effectiveness in analyzing complex lipid matrices and its utility in ensuring precision and reliability in food chemistry and nutritional analysis (Yen et al., 2010).
- Comparison of series 5 gas chromatography column performances from a variety of manufacturers for separation of chlorinated dibenzo-p-dioxins and dibenzofurans using high-resolution mass spectrometry.: This research compares the performance of various series 5 GC columns, including the Equity-5 Capillary GC Column, for analyzing persistent organic pollutants. The study underscores the column′s efficiency in environmental analytics, particularly in the separation of complex mixtures of hazardous organic compounds (Fishman et al., 2004).
Informations légales
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organes cibles
Eyes,Central nervous system
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
49.5 °F - closed cup
Point d'éclair (°C)
9.7 °C - closed cup
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Mahipal Sinnollareddy et al.
Expert opinion on drug metabolism & toxicology, 7(11), 1431-1440 (2011-09-03)
Invasive candidiasis has emerged over the last few decades as an increasingly important nosocomial problem for the critically ill, affecting around 2% of intensive care unit patients. Although poor outcomes associated with invasive candidiasis among critically ill patients may relate
Oluwaseun Egunsola et al.
European journal of clinical pharmacology, 69(6), 1211-1221 (2013-01-18)
To determine the safety of fluconazole in neonates and other paediatric age groups by identifying adverse events (AEs) and drug interactions associated with treatment. A search of EMBASE (1950-January 2012), MEDLINE (1946-January 2012), the Cochrane database for systematic reviews and
Jayantha Thiyanaratnam et al.
Journal of drugs in dermatology : JDD, 9(10), 1272-1275 (2010-10-15)
Fluconazole uncommonly causes Stevens-Johnson syndrome. A young Indian man who developed this adverse effect after his second dose of fluconazole is described. The characteristics of previously reported individuals with fluconazole-associated Stevens-Johnson syndrome and toxic epidermal necrolysis are also summarized: three
Raymond A Smego et al.
Medicine, 90(4), 237-249 (2011-06-23)
The treatment of Candida infective endocarditis generally involves infected valve removal accompanied by antifungal therapy with amphotericin B or a lipid-based derivative, with or without flucytosine. While often used as chronic suppressive therapy in these patients, the precise role for
Daniel K Benjamin et al.
JAMA, 311(17), 1742-1749 (2014-05-06)
Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown. To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique